Last reviewed · How we verify

Yang Jianjun, PhD — Portfolio Competitive Intelligence Brief

Yang Jianjun, PhD pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
nab-paclitaxel, lobaplatin, and S-1 nab-paclitaxel, lobaplatin, and S-1 marketed
Adebrelimab combined with SOX regimen Adebrelimab combined with SOX regimen marketed PD-L1 inhibitor PD-L1 Oncology
nab-paclitaxel，Cisplatin nab-paclitaxel，Cisplatin marketed Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (cisplatin) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 2 shared drug classes
  2. Samsung Medical Center · 2 shared drug classes
  3. Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
  4. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  5. CStone Pharmaceuticals · 1 shared drug class
  6. Celltrion · 1 shared drug class
  7. Biocad · 1 shared drug class
  8. Chinese Academy of Medical Sciences · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Yang Jianjun, PhD:

Cite this brief

Drug Landscape (2026). Yang Jianjun, PhD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yang-jianjun-phd. Accessed 2026-05-16.

Related